Clinical CAR-T Capabilities
Challenge from the Client
A global manufacturer of biopharmaceuticals was launching clinical trials of a new myeloma CAR-T therapy and needed to serve its clinical cancer patient population in the timeliest manner, by the end of a year.
Our Approach & Solution
Utilizing our proprietary service and product technologies, IPS worked to masterplan our client’s requirements by executing a one-week Inceptioneering study to obtain initial funding followed by the deployment of our iCON ÜBERcellFLEX PODs to put the proper assets in place and meet the critical schedule milestones.
The Results
The new facility and equipment assets were conceived, designed, fabricated, acceptance tested, commissioned and qualified to receive 1st patient samples in less than a year.
Related Molecules
Gene Therapy Facility
Read MoreOur client needed an efficient design for their gene biologics plant within an existing building with limited space for air handlers and mechanical equipment.
Commercial Manufacturing of Autologous Muscle Derived Cell (AMDC) products
Read MoreApplying industry-leading knowledge and expertise to support CGMP-compliant manufacturing process scale-up.
Clinical Lentivirus/AAV Manufacturing Facility
Read MoreA fast-tracked execution strategy for gene therapy manufacturing requiring “out of the box” thinking.
Site Selection for an Advanced Gene Therapy Company
Read MoreOur client was looking for a new site for their 2000L scale gene therapy manufacturing facility in a very saturated real estate market.
Mammalian Cell Culture to COVID-19 Vaccine Adjuvant in 3 weeks
Read MoreSoon after the COVID-19 outbreak, our client's direction shifted quickly from a mammalian cell culture facility to a COVID-19 vaccine adjuvant production facility.
Delivering a New Building with Two Project Teams
Read MoreProvided a client and building tenant with construction management services for the interior fit-out of a new 50,000sf pharmaceutical testing facility while a separate vendor constructs the core & shell for the landlord.
